SG Americas Securities LLC Sells 34,931 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

SG Americas Securities LLC lowered its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 74.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,252 shares of the company's stock after selling 34,931 shares during the period. SG Americas Securities LLC's holdings in Keros Therapeutics were worth $487,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Barclays PLC lifted its holdings in Keros Therapeutics by 29.0% in the third quarter. Barclays PLC now owns 49,511 shares of the company's stock worth $1,578,000 after acquiring an additional 11,118 shares during the last quarter. Braidwell LP raised its holdings in shares of Keros Therapeutics by 18.7% during the third quarter. Braidwell LP now owns 1,357,309 shares of the company's stock valued at $43,271,000 after buying an additional 213,444 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Keros Therapeutics by 42.1% during the third quarter. Bank of New York Mellon Corp now owns 144,409 shares of the company's stock valued at $4,604,000 after buying an additional 42,771 shares during the last quarter. CHI Advisors LLC raised its holdings in shares of Keros Therapeutics by 1.4% during the third quarter. CHI Advisors LLC now owns 407,633 shares of the company's stock valued at $12,995,000 after buying an additional 5,515 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Keros Therapeutics by 4.8% during the third quarter. Swiss National Bank now owns 45,600 shares of the company's stock valued at $1,454,000 after buying an additional 2,100 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Trading Up 1.5 %

NASDAQ:KROS traded up $0.95 during midday trading on Friday, hitting $62.66. 166,938 shares of the stock were exchanged, compared to its average volume of 365,406. Keros Therapeutics, Inc. has a one year low of $27.02 and a one year high of $73.00. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -12.05 and a beta of 1.26. The business has a 50-day moving average price of $62.65 and a two-hundred day moving average price of $45.16.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Friday, March 1st. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $0.14 million for the quarter. During the same quarter last year, the firm posted ($1.09) earnings per share. Sell-side analysts forecast that Keros Therapeutics, Inc. will post -5.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Truist Financial reaffirmed a "buy" rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Wednesday, March 13th. Wedbush reaffirmed an "outperform" rating and set a $86.00 price target on shares of Keros Therapeutics in a report on Thursday, February 29th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Friday, March 1st. Wells Fargo & Company assumed coverage on Keros Therapeutics in a report on Friday, December 8th. They set an "overweight" rating and a $60.00 price target on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $86.00.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.